Table 1. Characteristics of PwCF and MDR Pa isolates.
| Isolate | Age at sampling(years) | Sex | Comment | Ciprofloxacin | Piperacillin± Tazobactam |
Ceftazidime/Cefepime | Imipenem/Meropenem |
|---|---|---|---|---|---|---|---|
| 1 | 31.7 | M | Mucoid | R | R | R | R |
| 2 | 22.9 | F | -/- | R | R | R | R |
| 3 | 31.0 | F | -/- | R | R | R | R |
| 4 | 12.1 | M | Mucoid | R | R | R | R |
| 5 | 26.2 | F | -/- | R | R | R | R |
| 6 | 24.0 | F | -/- | R | R | R | R |
Resistance was determined according to zone diameter breakpoints for Pa (EUCAST, version 13.0, published December 2022). Isolates 2 and 5 were derived from one individual patient with a time lag of 3.3 y.
MDR, multiple drug resistance; PwCF, people with cystic fibrosis; R, resistance to indicated antibiotic.